JP2025509567A5 - - Google Patents

Info

Publication number
JP2025509567A5
JP2025509567A5 JP2024554783A JP2024554783A JP2025509567A5 JP 2025509567 A5 JP2025509567 A5 JP 2025509567A5 JP 2024554783 A JP2024554783 A JP 2024554783A JP 2024554783 A JP2024554783 A JP 2024554783A JP 2025509567 A5 JP2025509567 A5 JP 2025509567A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/015347 external-priority patent/WO2023177772A1/en
Publication of JP2025509567A publication Critical patent/JP2025509567A/ja
Publication of JP2025509567A5 publication Critical patent/JP2025509567A5/ja
Pending legal-status Critical Current

Links

JP2024554783A 2022-03-17 2023-03-16 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法 Pending JP2025509567A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320961P 2022-03-17 2022-03-17
US63/320,961 2022-03-17
US202263350503P 2022-06-09 2022-06-09
US63/350,503 2022-06-09
PCT/US2023/015347 WO2023177772A1 (en) 2022-03-17 2023-03-16 Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (2)

Publication Number Publication Date
JP2025509567A JP2025509567A (ja) 2025-04-11
JP2025509567A5 true JP2025509567A5 (cg-RX-API-DMAC7.html) 2026-03-24

Family

ID=86054295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554783A Pending JP2025509567A (ja) 2022-03-17 2023-03-16 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法

Country Status (9)

Country Link
EP (1) EP4493280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509567A (cg-RX-API-DMAC7.html)
KR (1) KR20240159849A (cg-RX-API-DMAC7.html)
CN (1) CN119677534A (cg-RX-API-DMAC7.html)
AU (1) AU2023236126A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245946A1 (cg-RX-API-DMAC7.html)
IL (1) IL315405A (cg-RX-API-DMAC7.html)
MX (1) MX2024011298A (cg-RX-API-DMAC7.html)
WO (1) WO2023177772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617776A (zh) * 2024-07-10 2026-05-01 美商再生元醫藥公司 治療smarcb1缺陷型癌症之方法
CN119632993B (zh) * 2024-12-04 2025-09-23 安徽医科大学 他泽司他在制备治疗急性肾损伤的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
JP7743314B2 (ja) * 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Similar Documents

Publication Publication Date Title
TWI890661B (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
JP7126941B2 (ja) がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
AU784971B2 (en) Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
JP2022050618A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
JP2019515008A5 (cg-RX-API-DMAC7.html)
HRP20220014T1 (hr) Postupci liječenja raka kože davanjem inhibitora pd-1
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2023505218A5 (cg-RX-API-DMAC7.html)
JP2021514945A5 (cg-RX-API-DMAC7.html)
JP2011507932A5 (cg-RX-API-DMAC7.html)
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2022512851A5 (cg-RX-API-DMAC7.html)
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
JP2025134086A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
JP2023519807A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2025509567A (ja) 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2025517336A5 (cg-RX-API-DMAC7.html)
CN118697865A (zh) 治疗淋巴瘤的药物组合
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
RU2024129390A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1